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Abstract
Background: The transcription factor Tcfap2c has been demonstrated to be essential for various processes during
mammalian development. It has been found to be upregulated in various undifferentiated tumors and is implicated with
poor prognosis. Tcfap2c is reported to impinge on cellular proliferation, differentiation and apoptosis. However, the
physiological consequences of Tcfap2c-expression remain largely unknown.
Methodology/Principal Findings: Therefore we established a gain of function model to analyze the role of Tcfap2c in
development and disease. Induction of the transgene led to robust expression in all tissues (except brain and testis) and
lead to rapid mortality within 3–7 days. In the liver cellular proliferation and apoptosis was detected. Accumulation of
microvesicular lipid droplets and breakdown of major hepatic metabolism pathways resulted in steatosis. Serum analysis
showed a dramatic increase of enzymes indicative for hepatic failure. After induction of Tcfap2c we identified a set of 447
common genes, which are deregulated in both liver and primary hepatocyte culture. Further analysis showed a prominent
repression of the cytochrome p450 system, PPARA, Lipin1 and Lipin2. These data indicate that in the liver Tcfap2c represses
pathways, which are responsible for fatty acid metabolism. In the intestine, Tcfap2c expression resulted in expansion of
Sox9 positive and proliferative active epithelial progenitor cells resulting in dysplastic growth of mucosal crypt cells and loss
of differentiated mucosa.
Conclusions: The transgenic mice show that ectopic expression of Tcfap2c is not tolerated. Due to the phenotype observed,
iTcfap2c-mice represent a model system to study liver failure. In intestine, Tcfap2c induced cellular hyperplasia and
suppressed terminal differentiation indicating that Tcfap2c serves as a repressor of differentiation and inducer of
proliferation. This might be achieved by the Tcfap2c mediated activation of Sox9 known to be expressed in intestinal and
hepatic stem/progenitor cell populations.
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Introduction
The family of Activator Protein-2 (AP-2) transcription factors is
highly conserved in mice (Tcfap2a–e) and humans (TFAP2A–E).
Tcfap2a, as first protein of the transcription factor family was
isolated from HeLa cells in 1988 [1], followed by the isoforms
Tcfap2b [2], Tcfap2c [3], Tcfap2d [4] and Tcfap2e [5]. AP-2
proteins have been demonstrated to modulate various signaling
pathways during development, cell growth, differentiation and
apoptosis [6,7,8,9,10]. AP-2 proteins are known to orchestrate the
balance between cellular growth and differentiation and are
essential for maintaining cellular homeostasis [11].
During murine development Tcfap2c expression is restricted
spatiotemporal to facial and limb mesenchyme, extraembryonic
tissue, primordial germ cells, peripheral nervous system, neural-
crest cells, dorsal telencephalon and various epithelia of the
developing embryo [12]. In adults, its expression is limited to the
developing breast, where loss of Tcfap2c blocks branching
morphogenesis of the mammary gland before puberty [13].
Deficiency of Tcfap2c causes early embryonic lethality on day
7.5 dpc due to a defect in the extraembryonic compartment.
Tcfap2c is required to maintain the extraembryonic lineages and
the undifferentiated state of trophoblast stem cells [9,14]. Further,
conditional deletion of Tcfap2c leads to loss of primordial germ
cells short after specification on day 8.0 dpc caused by de-
repression of somatic differentiation of PGC [15]. Additionally,
conditional deletion of Tcfap2c affects neurogenic basal progenitor
fate at mid-neurogenesis in the developing cortex [16].
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variety of solid tumors in humans. TFAP2C is reported to be
upregulated in breast cancer [17,18,19,20], in squamous cell
carcinoma (SCC) [21], in germ cell tumors and ovarian cancer
[22,23]. In mammary cancer, TFAP2C expression results in
increased progression of the tumors [24]. In general, Tcfap2c is
often found in undifferentiated cells or progenitor cell populations
and represses differentiation during development as well as in
cancer. Several studies demonstrated a variety of target genes for
TFAP2C in breast cancer tissue and cell lines [25,26,27,28,29]. In
breast cancer TFAP2C transactivates the expression of HER-2/
neu (ErbB2) [30] and estrogen receptor genes [29]. TFAP2C has
been shown to regulate the cyclin-dependent kinase inhibitor
(p21CIP1/CDKN1A) in breast cancer cell lines, but data are
controversial. While in MDA MB-231 cells TFAP2C activates p21
and represses proliferation, in MCF7 cells TFAP2C suppresses
p21 [28,31]. Hence ectopic transgene induction is likely to have
major effects and also mimics the reactivation of expression
observed in some solid tumor types. Better knowledge on the set of
Tcfap2c target genes and affected pathways in different tissues
would be beneficial for the interpretation of the results. Therefore
we established a mouse model, in which Tcfap2c can be activated
in an inducible and reversible manner in somatic tissues, taking
advantage of the tetracycline-dependent regulatory system.
Results
Generation of dox-inducible Tcfap2c transgenic mice
We had previously established mouse embryonic stem cell
(ESC) lines harboring the Tcfap2c-cDNA 39 of the Col1a1 locus
under control of a tetracycline responsive element (Col1a1::TetO-
Tcfap2c). There, the reverse tetracycline transactivator (M2-rtTA)
is integrated in the ROSA26 locus (ROSA26::rtTA) and expressed
by its endogenous promotor (Fig.1 A) [14]. The ESC-lines
displayed doxycycline-dependent induction of transgenic Tcfap2c
(Fig.1 B) after 48 h and were used to generate transgenic mice.
Mice harboring both, the Col1a1::TetO-Tcfap2c and RO-
SA26::rtTA transgenes named inducible Tcfap2c (iTcfap2c)
animals were selected for experiments and littermates were used
as controls.
Doxycycline dependent expression of Tcfap2c in adult
mice
To determine the levels of Tcfap2c-induction in various tissues
of adult mice, we analyzed animals that were given doxycycline
(dox) by drinking water for 5 days. Tissues were collected and
analyzed by immunohistochemistry. Highest levels of Tcfap2c
were detected in gastrointestinal tract, liver, gallbladder, skin and
uterus (Fig.1 C–G). Lower levels were found in heart, pancreas,
spleen, breast, kidney, lung, and bone marrow (Fig.1 H–N).
Evaluation of the distribution of transgene expression revealed
that the expression varied within the tissues. Strong and uniform
expression was detected in hepatocytes of the liver, cells of the
extrahepatic bile ducts, intestinal crypt- and villus-cells, stomach,
epithelial cells of the epidermis and the endometrial cells of the
uterus (Table S1). In brain and testis tissue, no induction was
detected. This might be the result of poor dox-penetration due to
the blood–brain and blood-testis barrier. Using RT-PCR,
transgene expression in liver, kidney and intestine was verified
(not shown). iTcfap2c-mice that were not exposed to dox did not
show any detectable expression of the Tcfap2c transgene (Fig.1 P,
R, compared to O, Q). Hence, these data show that we had
established a dox-dependent conditional transgenic system for the
induction of Tcfap2c.
Induction of Tcfap2c causes morbidity
Next, we assessed the physiological consequences of transgene
induction. After administration of dox (0.1 mg/ml) in the drinking
water, iTcfap2c-animals became lethargic lost up to 15% of their
weight (Fig.2 B) showed signs of dehydration and died within 6-7
days (Fig.2 A). Administration of dox via intraperintoneal (i.p.)
injection lead to death within 4 (0.5 mg/d, n=6) or 3 (1 mg/d,
n=17) days. Control animals treated 20 days with dox in the
drinking water or by i.p.-injection, showed no signs of morbidity
(Fig.2 A).
To identify the cause of lethality, we next analyzed metabolic
parameters in the blood/serum. Therefore, iTcfap2c (n=9) and
control animals (n=7) were treated with dox (0.5 mg/d) three
times (0, 24 and 48 h) and blood was collected after 52 h. The
iTcfap2c-mice showed elevated levels of aspartate transaminase,
alanine transaminase and alkaline phosphatase (Fig. 2 C-E),
enzymes indicative for acute liver failure. Furthermore serum
levels of lipase and amylase were increased. These are markers for
pancreatic injury (Fig.2 F–G). Also, five mice showed increased
lactate dehydrogenase levels, a marker of general tissue breakdown
(Fig.2 H). The fact, that we did not detect an increase of CD45
common leukocyte antigen staining in liver and intestine, indicated
that transgenic expression of Tcfap2c did not result in the
induction inflammatory processes (not shown). These data suggest
that induction of Tcfap2c leads to liver failure. To achieve robust
transgene induction and minimize secondary effects from
prolonged Tcfap2c induction all further analyses were carried
out with iTcfap2c animals treated with 0.5 mg dox i.p. at 0 h,
24 h and 48 h followed by analysis on day 3 (72 h).
Expression of Tcfap2c in the liver results in increased
proliferation, apoptosis and microvesicular steatosis
The immunohistochemical analyses demonstrated strong
induction of Tcfap2c in hepatocytes and the serum analysis
indicated liver failure. Since Tcfap2c has been described to
affect cellular proliferation as well as cell death [8,32], we
analyzed cellular proliferation and apoptosis. In liver sections of
iTcfap2c animals the number of proliferating cells was
significantly increased (14.0%) when compared to control
sections (0.5%) (Fig.3 A). To analyze whether the activation of
proliferation is a cell-intrinsic effect caused by upregulation of
Tcfap2c in these cells, we established an in vitro culture of
primary hepatocytes from iTcfap2c livers. The cultures were
treated with dox for 3 days in order to compare the results with
the in vivo situation. In addition, primary hepatocytes isolated
from iTcfap2c animals showed significant induction of prolifer-
ation (Fig.3 B). These results indicate that increased proliferation
is a cell intrinsic primary effect caused by Tcfap2c expression in
vitro and in vivo.
Upon close examination an increased number of cells with
condensed cytoplasm were detected in the liver of iTcfap2c mice
after dox-treatment. Most of those cells were positive in TUNEL
assay indicative for apoptosis (Fig.3 C) Hence, ectopic expression
of Tcfap2c led to an increase in both, proliferation and
apoptosis.
In addition, morphological and metabolic changes were
observed. Most hepatocytes of iTcfap2c animals displayed
vesicular bodies indicative for microvesicular steatosis (Fig.3 D).
This condition (characterized by cytoplasmic fat vesicles (lipo-
somes) that do not displace the nucleus) was detected in more than
50% of the hepatocytes using Oil-Red-O staining (Fig.3 D). The
accumulation of fat was also detected in iTcfap2c primary
hepatocytes (Fig.3 E). In addition, transmission electron micros-
copy analysis of the liver showed lack of glycogen storage in
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Generation and Analysis of Tcfap2c-Inducible MiceFigure 1. Generation of iTcfap2c-mice. Schematic representation of transgenes used to produce Tcfap2c-inducible ES cells and mice. ES cells
containing M2-rtTA expressed under control of the Rosa26 promoter were retargeted at the 39 UTR of the Col1a1 locus by insertion of the murine
Tcfap2c-cDNA under control of the tetracycline responsive element (TetOP) (pA, polyadenylation signal). (B) Western blot analysis of doxycyline (dox)
dependent Tcfap2c induction in transgenic ES cells. (C–N) Immunohistochemical detection of Tcfap2c protein on sections from iTcfap2c-mice after
dox-induction. Lack of Tcfap2c expression in untreated iTcfap2c mice in skin (P) and stomach (R) compared to dox induced iTcfap2c tissue (O,Q). Scale
bars=100 mm.
doi:10.1371/journal.pone.0022034.g001
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PLoS ONE | www.plosone.org 3 July 2011 | Volume 6 | Issue 7 | e22034iTcfap2c mice compared to controls. Furthermore mitochondria
were abnormally bright and increased mitophagy was observed
indicating mitochondrial damage. Since impaired mitochondria
are no longer able to perform beta-oxidation of fatty acids in the
mitochondrial matrix, this helps in explaining the observed
steatosis (Fig.3 E).
Figure 2. iTcfap2c-mice show strong morbidity in a dox-dependent manner. (A) Kaplan-Meier plot showing survival after dox treatment.
Green line: iTcfap2c-mice receiving dox via drinking water (dw) (0.1 mg/ml, n=6). Blue and red line: iTcfap2c-mice receiving dox via intra peritoneal
injection (i.p.) (blue: 1 mg/day, n=33), (red: 0.5 mg/day n=12). Black line: control mice (0.1 mg/ml dox by in dw for 20 days). (B) Weight of iTcfap2c
(red) and ctrl animals (black), which received 0.5 mg dox i.p. per day (n=12). (C–H) Biochemical blood serum analysis. Enzyme activity was measured
as the concentration of substrate converted per minute (1 enzyme unit=1 mmol substrate/min) in units/ liter. iTcfap2c (n=9) and ctrl animals (n=7)
were induced with 1 mg/ml dox per day. Blood samples were collected the third day.
doi:10.1371/journal.pone.0022034.g002
Generation and Analysis of Tcfap2c-Inducible Mice
PLoS ONE | www.plosone.org 4 July 2011 | Volume 6 | Issue 7 | e22034Figure 3. Tcfap2c increases proliferation and induces hepatic steatosis. (A) Percentage of proliferating Ki67 positive hepatocytes in iTcfap2c
(n=5) and ctrl mice (n=4) (B) Percentage of proliferating hepatocytes in cell culture, as the number of EdU positive cells. Error bars represent
standard deviations. ***p#0.0001, **p#0.001 (C) Immunohistochemical staining of liver for Ki67 (proliferation, upper panel) and TUNEL staining
positive (apoptosis, lower panel). (D) HE (middle panel) and Oil Red-O (lower panel) staining showing fat accumulation and microvisicular steatosis.
(E) Tcfap2c immunohistochemistry (upper panel) and Oil-Red O staining (lower panel) of primary hepatocytes. (F) Transmission electron microscope
images of iTcfap2c and ctrl liver. Hepatocytes from iTcfap2c mice are filled with lipid droplets (L); Dark and dense mitochondria in ctrl cells but bright
mitochondria in iTcfap2c cells were evidence for mitochondria damage. Glycogen granules (G) were visible only in ctrl cells. Scale bars=100 mm.
doi:10.1371/journal.pone.0022034.g003
Generation and Analysis of Tcfap2c-Inducible Mice
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lipid and glucose metabolism
To determine which genes were differentially expressed upon
Tcfap2c-induction microarray analysis was performed using liver
samples (n=8) (Fig.4 A). Unpaired t-test with a p-value cut-off of
0.05 and a 2-fold gene transcript change were used as filters. A
total of 1389 differentially expressed transcripts was identified and
is shown in a hierarchical cluster heat map (Fig. 4 B, Full gene list
Table S6). Next, the gene expression profile from iTcfap2c-liver
tissue was compared to the gene expression profile of in vitro
cultured iTcfap2c- hepatocytes. Analysis of both expression
profiles revealed a set of 447 common genes, which are
deregulated in both liver and hepatocytes as shown in the Venn
diagram (Fig. 4, C). We reasoned that these 447 genes represent
the genes directly affected by the upregulation of Tcfap2c. Hence
further analyses were carried out using the 447 commonly
deregulated genes. We next addressed the question, whether this
set of genes could be involved in the pathomorphological changes
i.e. the steatosis, proliferation and apoptosis in the liver of iTcfap2c
mice. Ingenuity Pathway analysis (IPA) software was used to assist
in biological interpretation of the deregulated genes. Interestingly,
the gene-set clustered to functional categories regulating ‘lipid
metabolism’, ‘hepatic systemic diseases’ and ‘other metabolic
processes’ (Table S2). The downregulation of these metabolic
pathways is in line with the steatosis observed after induction of
Tcfap2c (Fig.4 E, Table S3). The canonical pathway most
significantly affected (-log 11.072) was ‘metabolism of xenobiotics by
cytochrome P450’ (Fig.4 E, Table S3). The cytochrome P450 (CYP)
enzyme system is crucial for the metabolism of xenobiotics as well
as endogenous substances, such as fatty acids, prostaglandins and
steroids [33]. Of note, more than half of the regulated pathways
are linked to lipid metabolism processes and, as indicated by green
bars, most involved genes were downregulated. Also, genes
associated with glycolysis and gluconeogenesis were affected,
explaining the loss of glycogen granules after induction of Tcfap2c
(Fig.4 E). Interestingly, RXR mediated pathways were three of the
top most significant canonical pathways deregulated by Tcfap2c:
‘LPS/IL-1-mediated inhibition of RXR-function’,‘ PXR/RXR-activation’
and ‘FXR/RXR-activation’. This suggests a feedback loop, since
Tcfap2c has been reported to be induced by retinoic acid [3,6].
Next, we generated statistic gene networks, reflecting possible
direct and indirect gene interactions for the common gene list. IPA
analysis detected 13 highly scoring networks (Table S4). Six are
linked to lipid metabolism but there are also connections to cell
death, cell cycle, cellular development, cellular growth and
proliferation. Subsequently, differential expression of genes
encoding metabolic enzymes (Sult1e1, Adm, Mogat1, Adh1,
Arg1, Cyp3a11, Cyp3a25, Hao1, Pah, Uox, Lipc, Lipin1, Lipin2)
as well as the key regulators of lipid metabolism (peroxisome
proliferator-activated receptor alpha and delta, PPARA, PPARD)
were verified by RT-PCR in liver tissues as well as in hepatocyte
cultures of iTcfap2c mice (Fig.4 D). All selected genes were
deregulated in agreement with the array analysis.
Furthermore, Tcfap2c expression affects various signaling
cascades via transcriptional regulation of Fgfr3, Fgfr4, insulin-like
growth factor (IGF1) and hepatocyte growth factor activator
(Hgfac). Additionally, Tcfap2c induced the expression of cancer-
associated markers such as, CRIP1 a putative target gene of
TFAP2 in prostate cancer [34]. Also, the imprinted, maternally
expressed and non-protein coding transcript H19, which is highly
expressed in liver metastasis and other tumors was upregulated
upon activation of Tcfap2c (see Table S6). Thus, these data
provide molecular evidence for the oncogenic potential of Tcfap2c
observed in other studies [35].
To further understand the transcriptional networks controlled
by Tcfap2c we asked, whether the promoters of the 447 candidate
genes described here were bound by Tcfap2c. We performed a
meta-analysis on the genome-wide Chromatin-IP chip (ChIP-chip)
dataset of Tcfap2c occupied regions in trophoblast stem cells [36]
and detected an overlap of 77 genes, from which 47 were found
activated and 30 were repressed in our gene arrays (Table S7).
Further analysis using TRANSFAC software revealed, that 20 of
these genes had bona fide Tcfap2c binding sites within the
promotor region and represent the most likely candidates for a
direct regulation by Tcfap2c (Table S7, black). These genes were
(upregulated) Tcfap2c, Crip1, Hsbp1, Plp2, Crip2, Pdlim1, Jup,
Midn, Sox9, Vcl, PPARD, Ralgds, JunB, Rgl3, Tgfrbr1, Gab2
and (downregulated) Spn3, Fads2, Reep6, Fgfr4. These data
provide a framework for further understanding of Tcfap2c
regulated networks in development and disease.
Tcfap2c in the intestine led to changes in proliferation
and differentiation
Aside from the liver, the transgene was expressed in epithelial
cells of the crypts and villi of the intestinal lamina propria
mucosae, but not in the mesenchymal cells and the lamina
muscularis mucosae (Fig.5 A). Three days after Tcfap2c-induction,
the epithelial cells of the intestinal mucosa showed dysplastic
growth (Fig.5 A, B). The cells appeared morphologically
immature. The crypt-depth to villus-height was measured and
this ratio was significantly shifted from approx. 0.2 to 0.6 in
iTcfap2c-mice indicating strong hyperplasia (Fig.5 C). Further-
more, Ki67 staining revealed that the proliferative zone, which is
usually restricted to the base of the crypt, expanded to cover crypt
and villus upon induction of Tcfap2c. The progress and severity of
proliferation varied within the animals analyzed (Fig.6 A, B) but
could always be considered as hyperplastic when compared to
control animals (Fig.6 C).
We next addressed the question whether the proliferating cells
represent immature (progenitor cells) or differentiated cells, which
were forced back into cell-cycle. In the intestine, the progenitor
cells, which are responsible for constant renewal of the intestinal
tissue display high Ki-67 activity and express the HMG-group
transcription factor SOX9 [37,38,39]. Immunohistochemical
detection of Sox9 showed that all hyperplasic cells were positive
for Sox9 (Fig.7 A) suggesting an expansion of the progenitor
compartment. In parallel, the number of terminally differentiated
derivatives was dramatically reduced (absorptive enterocytes,
goblet cells, Paneth cells and enteroendocrine cells) as shown by
Alcian blue/periodic acid Schiff (PAS) staining (Fig. 7 B). So,
Tcfap2c mediated activation of Sox9 in liver and intestinal cells
might inhibit differentiation and induce a cell-type specific
progenitor program.
Discussion
Here, we generated a mouse model in which Tcfap2c could be
activated in an inducible and reversible manner by doxycycline in
a variety of tissues. Induction of transgenic Tcfap2c in adult mice
resulted in rapid lethality within 3–7 days depending on dox
concentration. The mice displayed liver steatosis resulting in
systemic organ failure and subsequently death of the animal.
Expression array experiments revealed that the induction of
Tcfap2c in the liver resulted in dramatic downregulation of
pathways responsible for lipid metabolism, which provides a link
to the molecular mechanism underlying the pathomorphological
phenotype. In the intestine, induction of Tcfap2c led to a dramatic
Generation and Analysis of Tcfap2c-Inducible Mice
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22034Figure 4. Genes regulated by Tcfap2c and deregulated pathways. (A) Affymetrix microarray gene expression analysis performed with RNA
extracted from livers of iTcfap2c (n=4) and ctrl (n=4) mice. (B) Heat map showing genes with at least twofold difference between any pair of
samples from different classes. Red and blue indicate higher and lower relative expression, respectively. (C) Venn diagram; commonly regulated
transcripts by Tcfap2c in vivo and in vitro are shown in the intersection part. (D) RT-PCR of RNA isolated from iTcfap2c and control liver (left column)
and Hepatocytes (right colum using the genes indicated (E) Top 18 most significantly regulated pathways are presented based on common gene lists
regulated by Tcfap2c.
doi:10.1371/journal.pone.0022034.g004
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concomitant loss of terminally differentiated cells.
The expression and induction pattern of the Tcfap2c transgene
closely mirrors the results reported from Oct4 [40] and EGFP-
inducible [41] transgenic mice, all taking advantage of the same
doxicycline-dependent and Rosa26-promotor driven rtTA-system.
Hence, the differences in induction of the transgene in the various
tissues are most likely due to the system used and not a result of a
specific role of the respective transgene.
The most striking pathomorphological effect of iTcfap2c-
induction was observed in the liver. Hepatocytes displayed an
altered proliferation, morphology and metabolism. The high
serum concentrations of liver specific enzymes and the increased
number of apoptotic hepatocytes are indicative of liver damage.
Increased proliferation of the liver could be a compensatory effect,
due to acute liver damage and cell death of hepatocytes suffering
from lipid accumulation and increased oxidative stress. Since this
increase was also seen in primary hepatocytes, induction of
proliferation is most likely a cell intrinsic consequence of Tcfap2c
expression.
Hepatocytes showed a fast occurring and strong microvesicular
steatosis by accumulation of lipids, indicating a shutdown of
metabolic enzymes. Gene expression further corroborated this
finding. Tcfap2c expression significantly influenced the expression
of genes that play a role in gylcerolipid metabolism, fatty acid
metabolism, xenobyotic metabolism as well as glycolysis as shown
by pathway analysis. In addition, the absence of glycogen together
with mitochondrial abnormalities detected by electron microsco-
py, were further hallmarks of impaired lipid beta-oxidation.
Further, downregulation of SDHC (succinate dehydrogenase
complex, subunit C, integral membrane protein) as well as
mitochondria associated cytochrome P450 enzymes (like Cyp27a1)
suggests that the observed phenotype might be caused in part by
dysfunctional mitochochondria.
Figure 5. Tcfap2c expression leads to dysplastic growth in the intestine. Immunhistochemical detection of Tcfap2c expression on intestinal
sections of iTcfap2c (A) and control mice (B). (C) Ratio of crypt length/villus length the area indicated. Length of villus was measured as the distance
from the intestinal muscularis mucosa to the villus-apex; length of the crypts was measured as distance from muscularis mucosae to the bottom of
the villus. ***p#0.0001, **p#0.001, Scale bar=100 mm.
doi:10.1371/journal.pone.0022034.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e22034Figure 6. Tcfap2c induces proliferation of the intestine. Sections of the intestine of iTcfap2c (A,B) and control (C) showing HE (upper panel)
and Ki67 staining. Scale bars=100 mm.
doi:10.1371/journal.pone.0022034.g006
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e22034The repression of a variety of cytochrome P450 (CYP) enzymes
after Tcfap2c induction strongly indicates the inhibition of omega-
oxidation processes. In addition, inhibition of CYP enzymes has
been reported in livers of patients with steatosis [42]. The
substrates of CYP enzymes include metabolic intermediates such
as lipids and steroidal hormones, as well as xenobiotic substances.
The pathway of the ‘xenobiotic metabolism by cytochrome P450’
is downregulated and is connected to the regulation of peroxisome
Figure 7. Induction of Tcfap2c results in expansion of the progenitor compartment. (A) Sox9 staining of the intestine iTcfap2c (upper
panel) and controls (lower panel). (B) Alcian blue-PAS staining of the intestine iTcfap2c (upper panel) and controls (lower panel). Arrowheads indicate
Paneth cells, found at the bottom of the crypts by blue coloring of their granules. Scale bar=100 mm.
doi:10.1371/journal.pone.0022034.g007
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tors. PPARA and the metabolic co-regulators (Lipin1, Lipin2)
were downregulated as well. Reduction of PPARA and Lipin1-2
decreases the hepatic capacity for fatty acid oxidation leading to
steatosis [43,44]. Further, PPARA regulates genes encoding
peroxisomal, microsomal and mitochondrial fatty acid metaboliz-
ing enzymes in the liver [45].
Due to the rapid death of the iTcfap2c-mice cellular
transformation was not observed. However, tumor-associated
genes were found up-regulated in iTcfap2c-mice. H19, an
imprinted gene that displays maternal monoallelic expression
during development and is reactivated during adult tissue
regeneration and hepatocellular carcinoma [46,47] was induced.
Also cysteine-rich intestinal protein 1 (CRIP1), an early marker of
mammary carcinoma [48] was up-regulated as a consequence of
Tcfap2c upregulation. So it seems conceivable, that sub-lethal
chronic and/or tissue specific induction of Tcfap2c might
eventually result in oncogenic transformation.
Furthermore, ectopic expression of Tcfap2c in adult mice
resulted in dysplastic growth of the epithelial cells of the mucosa in
the intestinal tract. There, induction of Tcfap2c resulted in an
expansion of the proliferative zone in the intestine. In parallel, we
observed the lack of terminally differentiated cells in the intestine
after induction of Tcfap2c indicated by the disappearance of PAS
positive cells. This phenotype can be obtained by two mechanisms
i) expression of Tcfap2c re-induces proliferation in differentiated
gut mucosal epithelial cells or ii) induction of Tcfap2c leads to
expansion of the undifferentiated progenitor cells and repression of
terminal differentiation. While scenario i) cannot be ruled out
formally, we favor scenario ii) the expansion of the progenitor
compartment, since virtual all proliferative intestinal epithelial cells
display immunoreactivity for Sox9, a marker for immature
progenitor cells [37].
How might Tcfap2c shut off the differentiation pathways in liver
and intestine? The meta-analysis, which demonstrated that 20 of
the deregulated genes harbor bona fide Tcfap2c binding sites (and
are bound by Tcfap2c) indicated that the SRY-box containing
gene 9, (Sox9) is a gene transactivated by Tcfap2c. Sox9 lineage
tracing showed that adult intestinal cells, hepatocytes and
pancreatic acinar cells are arising from Sox9-expressing progen-
itors [39]. Furthermore, adult hepatic stem/progenitor cells are
described to express Sox9 and seem to be the cellular source for
liver regeneration [49]. So, Tcfap2c mediated activation of Sox9
might induce the cell-type specific progenitor program in liver and
intestinal cells, leading to the inhibition/downregulation of the
differentiation markers. In addition, IPA analysis identified novel
transcription regulatory networks affecting proliferation and cell
death.
The role of Tcfap2c in repressing differentiation and supporting
proliferation has been reported in several systems. Tcfap2c helps
to maintain the undifferentiated state of primordial germ cells by
repressing mesodermal differentiation [15]. Additionally Tcfap2c
is highly expressed in undifferentiated germ cell tumors (carcino-
ma in situ and seminoma) and becomes downregulated in
differentiated germ cell tumors such as teratocarcinoma [22,23].
In early embryonic development Tcfap2c is essential for
trophoblast stem cell self-renewal and deletion of Tcfap2c leads
to a reduced proliferation and premature differentiation of
extraembryonic tissues [9,14]. Increased levels of Tcfap2c are
detected in poorly differentiated breast tumor samples [17].
MMTV-driven transgenic overexpression of Tcfap2c in the
mammary epithelium leads to increase in proliferation and an
impaired differentiation [32]. Of note, the cell cycle regulator and
human TFAP2C target gene CDNK1A/p21 [27,29] was not
isolated in our system. This could be due to epigenetic
modifications restricting access to the p21 locus or a lack of
appropriate co-factors in the tissues analyzed. Taken together we
propose the following model: Induction of Tcfap2c in the liver
leads to downregulation of metabolic pathways, i.e. indicators of
terminally differentiated cells. This dedifferentiation leads to an
induction of the proliferation. We hypothesize, that this is not
being tolerated by the system and results in death of the cells and
subsequently liver failure. In the intestine on the other hand we
observe a dramatic expansion of the progenitor compartment
highlighted by Sox9 expression. The turnover of intestinal
ephithelial cells is 3 days, so in iTcfap2c mice the terminally
differentiated cells of the villus are replaced by immature
progenitors from the crypt during this period of time. These
results further substantiate the role for Tcfap2c in supporting
proliferation and repressing differentiation in cellular compart-
ments, representing immature/progenitor cells.
Methods
Animals
All experiments were were conducted according to the german
law of animal protection and in accordance with the approval of
the local institutional animal care committees (Landesamt fu ¨r
Natur, Umwelt und Verbraucherschutz, North Rhine-Westphalia,
approval ID: #8.87-50.10.31.08.238). All efforts were made to
minimize the number of animals used and their suffering.
Generation of transgenic mice
Doxycycline-inducible Tcfap2c ESC cells [tg(Col1a1::TetO-
Tcfap2c)(R26::rtTA)] are described previously [14]. To generate
chimeric mice, C57BL/6J blastocysts injected with Tcfap2c
inducible ES cells were transferred into pseudopregnant foster
mice. Offspring of germ line-transmitting chimeric mice were
screened for the presence of the targeted ROSA26 and Col1a1
allele by PCR. The mice were registered with the mouse genome
informatics database, the allele was named Col1a1,tm1(tetO-
Tcfap2c)Hsc. (MGI:4949113).
Transgene induction
Experiments were carried out on adult mice (C57BL/6J x 129/
Sv) at 8–16 weeks of age. Mice were administered either 0.1 mg/
ml doxycycline (Sigma) in the drinking water supplemented with
10% succrose or by intra peritoneal (i.p.) injection of 1 or 0.5 mg
doxycycline dissolved in PBS. For cultured cells, doxycycline was
used at a concentration of 1 mg/ml.
Histological analysis
Tissue samples from double transgenic (iTcfap2c) and control
animals were either frozen in liquid nitrogen or fixed in 4%
buffered formalin overnight and embedded in paraffin. Frozen
tissue sections (10 mm) were incubated in 60% isopropyl alcohol,
stained for 10 minutes in Oil-Red-O solution and counterstained
with hematoxylin. Formalin fixed sections (2–5 mm) were stained
with hematoxylin and eosin (H&E) or Alcian blue/periodic acid
Schiff (PAS) to detect tissue proteoglycans. To detect apoptotic
cells, deoxynucleotidyl transferase dUTP nick end labelling Kit
(ApopTagHPeroxidase Kit, Chemicon/Millipore) was used. For
immunostaining, sections were incubated (4uC, overnight) using
the following primary antibodies: Tcfap2c (6E4; 1:500; Abcam),
Ki-67 (1:200, DAKO), Sox9 (1:200 R&D Systems) and subse-
quently with biotinylated secondary anti-mouse-antibodies
(DAKO) for 30 min., followed by incubation with avidin-coupled
Generation and Analysis of Tcfap2c-Inducible Mice
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e22034peroxidase (Vector Laboratories) for 1 h. Sections were photo-
graphed using Diskus software.
Morphometric analysis of the intestine
Intestine was dissected and fixed with 4% buffered formalin
for 24 h. Parts of the intestine (duodenum 1 cm, and jejunum
5 cm distal to the pyloric sphincter; ileum 1.5 proximal to the
ceacum) were fixed for another 24 h and subsequently para-
ffin embedded. Transverse tissue sections were stained with
H&E. From each section the depth of at least 4 crypts (from
the muscularis mucosa to the bottom of the villus) and the
overall height of the corresponding villi (from muscularis
mucosa to the villus apex) were determined, to analyze the
cryt/villus ratio.
Primary hepatocyte cell culture
ITcfap2c and control mice were anesthetized and livers were
perfused via the portal vein first for 10 minutes with Hanks
buffered saline (Gibco), without calcium or magnesium, supple-
mented with 100 mM EGTA and 5000 U Heparin and following
for 10 minutes with 0,05 % collagenase (Worthington) in Williams
Medium E (Gibco) supplemented with CaCl2 (2.5 M) and
Gentamycine (0.1 mg/ml). Livers were removed, mechanically
disrupted, filtered through a mesh (300 mm) and centrifuged at
300 rpm for five min. Vital cells were separated using Percoll
gradient centrifugation, washed once with Gey’s balanced salt
solution (GBSS) and platet on collagenated 24 well-Plates
(10
5 cells/well). ITcfap2c and control cells were treated with
doxycycline (1 mg/ml) and expression of Tcfap2c, proliferation
and fat accumulation were analyzed after different incubation
times.
Microarray procedures
The microarray study was carried out using Affymetrix Mouse
Gene ST 1.0 arrays (Affymetrix, Santa Clara, CA). Briefly, total
RNA was extracted from cells with RNAeasy kit including DNAse
digestion (Qiagen, Hilden, Germany). RNA integrity was assessed
using the Agilent 2100 Bioanalyzer (Agilent Technologies,
Bo ¨blingen, Germany). For the Affymetrix array, 300 ng of total
RNA were used. The arrays were washed and stained according to
the manufacturer’s recommendations and finally scanned in a
GeneChip scanner 3000 (Affymetrix). Normalization was calcu-
lated with RMA algorithm implemented in GeneSpringGX
software (Agilent Technologies, Bo ¨blingen, Germany). We used
free trial of Ingenuity software to analyze gene pathways and
networks affected by Tcfap2c. The raw microarray data have been
deposited in the Gene Expression Omnibus repository (accession
number GSE28692), which is a MIAME compliant database.
RT-PCR
Total RNA was isolated from cells and tissues by using RNeasy
Mini kit (Qiagen) according to the manufacturer’s instructions.
First-strand cDNA was synthesized from 500 ng total RNA using
SuperScriptIII reverse transcriptase (Invitrogen) according to the
manufacturers instructions. The PCR primer sequences are listed
in Table S5.
Protein analysis
For Western blot analysis, 20 mg of protein extract was run on a
10% polyacrylamide separating gel and blotted onto a PVDF
(polyvinylidendifluorid) membrane. Antibodies against the follow-
ing proteins were used Tcfap2c (1:500; 6E4/4; Abcam), b-Actin
(1:50000; Santa Cruz).
Cell proliferation analysis
10
5 primary hepatocytes per 24-well were grown for 48 h in the
presence or absence of 1 mg/ml doxycycline in Williams Medium
E (Gibco) (supplemented with glutamin, glucose, hepes pH 4,
antibiotics, hydrocortisone, insulin, DMSO and inosine). In vitro
proliferation was measured after 12 h incubation with EdU and
detected with the Click iTHEdU Imaging Kit (Invitrogen)
according the manufacturer’s instructions and counted in five
visual fields. The following antibodies and dilutions were used for
further immunofluorescence staining: rabbit antiTcfap2c poly-
clonal Ab (1:400; H77; Santa Cruz), Alexa-488 anti rabbit (1:1000;
DAKO) or Hoechst 33342 (1:2000; Invitrogen) for nuclear
staining. Cells were observed using an IM-DRB fluorescent
microscope (Leica).
Blood analysis
Mouse blood composition and blood chemistry were examined
52 h after the beginning of doxycycline treatment (1 mg/day).
Blood was collected in EDTA tubes (Sarstedt) and used for
complete blood count. Plasma was separated by centrifugation
8000 rpm and 4uC with ‘‘serum gel’’ tubes (Sarstedt) used for
biochemical analysis of enzyme activity and detection of non-
cellular blood composition.
Electron microscopy
ITcfap2c and control mice were sacrificed after 48 h doxycy-
cline treatment and liver sections were fixed immediately in an
aqueous solution of glutaraldehyde (2.5%) in 0.1 M sodium
cacodylate buffer (pH 7.4). Following fixation at 4uC over 2 days,
postfixation was started with 2% osmium tetroxide (0.1 M sodium
cacodylate buffer) over night at 4uC. Next, tissues were washed
two times in isotonic sodium cacodylate buffer (0.1 M; pH 7.4)
and dehydrated through a graded series of ethanol, embedding
was initiated in Epon 812 with a polypropylene oxide-Epon
mixture (1:1) over night. Polymerization was performed at 70uC
for 24 h. Thin sections were cut on a Leica LBK UM IV
ultramicrotome to 60 nm and stained with 3.5% uranyl acetate
and lead citrate according to standard protocols. Sections were
analyzed with a Phillips CM 10 transmission electron microscope
and digital picture analysis software (Olympus- SIS).
Statistical Analysis
Data are expressed as mean6SD. Statistical comparisons were
performed using Student’s t-test. p,0.05 was considered to be
statistically different.
Supporting Information
Table S1 Qualitative and quantitative analysis of in vivo
expressed Tcfap2c.
(PDF)
Table S2 IPA analysis of significant functional catego-
ries based on common genes regulated by Tcfap2c in
liver and hepatocyte cultures.
(PDF)
Table S3 IPA analysis of regulated canonical pathways
based on liver and hepatocyte common gene list.
(PDF)
Table S4 IPA analysis of transcriptional gene network
regulated by Tcfap2c in induced hepatocytes.
(PDF)
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Table S6 Gene array analysis: List of Tcfap2c deregu-
lated genes in the liver, hepatocyte culture and common
deregulated genes.
(XLSX)
Table S7 Meta-analysis of the genes detected using
the genome-wide Chromatin-IP-chip (ChIP-chip) da-
taset of Tcfap2c occupied regions in trophoblast stem
cells and comparing them to the dataset of 447
differentially expressed genes upon Tcfap2c induc-
tion in liver and hepatocytes. A total of 77 differentially
expressed genes were also detected using the ChIP-chip. 47 were
induced (red) and 30 were repressed (blue) upon Tcfap2c
induction in our experiments. 20 genes display bona fide Tcfap2c
binding sites within the promotor as revealed by TRANSFAC
analysis (black).
(XLSX)
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